Company Overview
About Shorla Oncology
Shorla Oncology is a specialty pharmaceutical company co-founded by Sharon Cunningham and Orlaith Ryan in 2019, headquartered in Cork, Ireland, with US operations in Westwood, Massachusetts. The company focuses on developing and commercializing oncology and rare disease drugs, with a particular emphasis on orphan and pediatric indications where treatment options are severely limited or where drug shortages threaten continuity of care. Shorla's approach centers on reformulating proven active pharmaceutical ingredients to improve administration, reduce toxicity, and ensure supply reliability for vulnerable patient populations.
Business Model & Competitive Advantage
The company's lead product is Enrylaze (calaspargase pegol), a long-acting recombinant asparaginase approved for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma in adults and pediatric patients. Enrylaze is approved in both the US and the European Union and addresses a critical gap created by repeated shortages of older asparaginase products. Shorla raised a $27M Series A round in 2022, with backing from investors including Jeito Capital, to fund commercial launch and pipeline expansion. The company markets Enrylaze in the US through a dedicated oncology sales force and has established EU distribution partnerships.
Competitive Landscape 2025–2026
Shorla differentiates by combining commercial agility — typical of small specialty pharma — with deep expertise in regulatory strategy for orphan and pediatric drug designations. Its pipeline targets additional oncology drugs facing access, formulation, or shortage challenges, positioning the company as a reliable partner to oncology centers that care for the most difficult-to-treat patient groups. The company has received Orphan Drug Designation and pediatric exclusivity protections that extend its commercial runway.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Karius
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
Compare Shorla Oncology with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Shorla Oncology? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Shorla Oncology Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Shorla Oncology vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →